Psychedelic medicine & neuropsychiatric biologics

01Overview and value chain

Markers: [EC: EU Clinical Trials Regulation & neuropsychiatric medicine standards | OECD: Bio-pharmaceuticals | Regulator: FDA (US), EMA (EU), NMPA (China)]

Psychedelic medicine uses psychoactive compounds — psilocybin, MDMA, 5-MeO-DMT — paired with structured psychotherapy to treat treatment-resistant psychiatric conditions, working primarily through serotonin 5-HT2A receptor agonism that triggers a burst of brain-derived neurotrophic factor (BDNF) and rapid synaptogenesis, reorganizing the rigid neural patterns associated with depression and PTSD. The field’s clearest 2026 win came from Compass Pathways, which announced in February 2026 that its second Phase 3 trial (COMP006) of COMP360 synthetic psilocybin met its primary endpoint in treatment-resistant depression. The field’s clearest setback came from Lykos Therapeutics (formerly MAPS), whose New Drug Application for MDMA-assisted therapy for PTSD was rejected by the FDA in August 2024 after an advisory committee review; the company restructured, cutting roughly 75% of its workforce, and remains focused on addressing the FDA’s concerns rather than having secured approval, a status that a May 2026 patient-facing update confirms is still current. A parallel, increasingly well-funded track avoids hallucinogenic effects entirely: Delix Therapeutics reported positive efficacy data for DLX-001 (zalsupindole) in October 2025 alongside FDA clearance of a Phase II trial design featuring at-home administration, aiming to prove its non-hallucinogenic psychoplastogen works without the clinic-based supervision classical psychedelics require. Beckley Psytech’s BPL-003, an intranasal 5-MeO-DMT formulation, reported positive Phase IIa topline data in May 2025 showing durable efficacy up to three months in treatment-resistant depression from a single dose — atai Life Sciences invested in Beckley Psytech in January 2024 and the two now report combined financial results. atai’s broader portfolio includes DemeRx’s noribogaine, an ibogaine metabolite cleared by the FDA for first-in-human testing as a non-psychoactive, lower-cardiotoxicity alternative to ibogaine itself, part of a wave of state-level funding (including a $50 million Texas UTHealth/UTMB ibogaine research consortium announced in December 2025). In China, the Shanghai Institute of Materia Medica (CAS) operates a cryo-electron-microscopy structural biology center (established 2018) studying GPCRs — the receptor class serotonin 5-HT2A belongs to — supporting China’s near-exclusive focus on non-hallucinogenic psychoplastogen design rather than classical psychedelic-assisted therapy, given the country’s strict narcotics laws.

The key directions of psychedelic medicine and neuropsychiatric biologics are:

1. Classical psychedelic-assisted therapy: purified synthetic psychedelics (psilocybin, MDMA) administered during long supervised sessions with trained therapists, targeting depression, PTSD and addiction.
2. Non-hallucinogenic psychoplastogens (next-gen): engineered molecules that retain the synaptogenesis-triggering therapeutic effect without any trip, designed for take-home use without clinical supervision.
3. Biased 5-HT2A agonism: molecular engineering to activate only the Gq-protein signaling pathway responsible for neuroplasticity while blocking the beta-arrestin-2 pathway responsible for hallucination.
4. Novel delivery routes: intranasal and other nose-to-brain delivery systems that bypass first-pass liver metabolism for faster onset and shorter, less clinically burdensome dosing sessions.

Sectoral value chain

[AI screening & molecular design] ──> [Organic synthesis / biocatalytic production] ──> [In vitro receptor-signaling assays]
                      │                                        │                                       │
          (Psychoplastogen candidates)              (GMP precision purification)             (Biased-signaling profiling)
                                                                                                       │
  [Clinical administration (GMP)] <──── [Preclinical synaptogenesis studies (in vivo)] <─────────────┘

Value chain levels

Cross-cutting technologies of the sector:

• Biased 5-HT2A signaling: engineering a molecule to selectively activate only the Gq-protein neuroplasticity pathway upon binding the 5-HT2A receptor while blocking the beta-arrestin-2 pathway responsible for hallucinations, the core design goal of non-hallucinogenic psychoplastogens.
• In vivo two-photon confocal microscopy: live brain imaging through a cranial window in lab mice, tracking individual cortical neurons before and after dosing to directly visualize new dendritic-spine (synapse) formation within 24 hours.
• Intranasal nose-to-brain delivery: precision nasal-spray systems that deliver lipophilic molecules directly to the brain via the olfactory nerve, bypassing systemic circulation and first-pass liver metabolism for a faster onset of action.

02US

The United States hosts the field’s most advanced clinical programs, including both its highest-profile regulatory setback and its most advanced non-hallucinogenic candidate.

Lykos’s FDA rejection and restructuring, Delix’s at-home psychoplastogen trial clearance, FDA regulatory pathway

• Lykos Therapeutics (formerly MAPS): the FDA rejected its New Drug Application for MDMA-assisted therapy for PTSD in August 2024 following an advisory committee review; the company restructured, cutting roughly 75% of its workforce, and as of a May 2026 status update remains focused on addressing the FDA’s concerns rather than holding an approval.
• Delix Therapeutics: reported positive efficacy data for its lead non-hallucinogenic psychoplastogen DLX-001 (zalsupindole) in October 2025, alongside FDA clearance of a Phase II trial design featuring at-home administration rather than clinic-based supervised dosing.
• Regulatory pathway: the FDA’s Breakthrough Therapy designation continues to accelerate several programs in this Industry, though the Lykos rejection demonstrates that designation alone does not guarantee approval, particularly for therapies bundling a drug with a mandatory psychotherapy protocol.

03CN

China has focused almost exclusively on non-hallucinogenic psychoplastogen development, leveraging strong structural biology capability while avoiding classical psychedelic-assisted therapy under strict narcotics law.

SIMM’s cryo-EM structural biology, non-hallucinogenic focus under narcotics law, NMPA approval pathway

• Shanghai Institute of Materia Medica (SIMM, CAS): operates a cryo-electron-microscopy structural biology center (established 2018) studying G-protein-coupled receptors (GPCRs) — the receptor class serotonin 5-HT2A belongs to — providing atomic-resolution structural data that supports AI-driven design of biased, non-hallucinogenic agonists.
• Non-hallucinogenic focus: China’s strict narcotics legislation makes clinical use of classical hallucinogens in psychiatry essentially unworkable, so Chinese biotech developers concentrate entirely on non-hallucinogenic psychoplastogens positioned as standard prescription neuropsychiatric tablets.
• NMPA pathway: candidate molecules developed in China are designed from the outset to go through NMPA’s standard pharmaceutical approval process rather than a specialized psychedelic-therapy pathway, avoiding the therapist-supervision protocol requirements that apply to hallucinogen-based treatments elsewhere.

04EU

Europe hosts the field’s clearest 2026 clinical win alongside a leading intranasal rapid-acting psychedelic and the venture-holding company backing both.

Compass Pathways’ second positive Phase 3 trial, Beckley Psytech’s intranasal 5-MeO-DMT, atai’s ibogaine-metabolite program

• Compass Pathways: announced in February 2026 that its second Phase 3 trial (COMP006) of COMP360 synthetic psilocybin met its primary endpoint in treatment-resistant depression, building on its first positive Phase 3 result.
• Beckley Psytech: its BPL-003 intranasal 5-MeO-DMT formulation reported positive Phase IIa topline data in May 2025 showing durable efficacy up to three months in treatment-resistant depression from a single dose, with a session substantially shorter than a multi-hour psilocybin trip; atai Life Sciences invested in Beckley Psytech in January 2024 and the two now report combined financial results.
• atai Life Sciences: backs a broad derivative portfolio including DemeRx’s noribogaine, an ibogaine metabolite cleared by the FDA for first-in-human testing as a non-psychoactive, lower-cardiotoxicity alternative to ibogaine, part of a wave of state-level funding including a $50 million Texas UTHealth/UTMB ibogaine research consortium announced in December 2025.

05Leading companies and research institutes

06Tech stack and innovations

The psychedelic-medicine and neuropsychiatric-biologics stack pairs structural biology and synthetic-biology production methods with precision delivery technology:

1. Enzymatic biosynthesis of psilocybin:
   • Rather than costly multi-step chemical synthesis, a four-enzyme metabolic pathway from Psilocybe fungi (decarboxylase, kinase, methyltransferase and hydroxylase) is engineered into recombinant yeast or E. coli, producing purified psilocybin via fermentation at lower cost and higher batch consistency.
2. High-resolution cryo-electron microscopy (cryo-EM):
   • Atomic-level mapping of 5-HT2A and related GPCR receptor structures in complex with candidate agonist molecules, revealing precise binding angles and hydrogen bonds used to computationally optimize biased, non-hallucinogenic psychoplastogen design.
3. Preparative reversed-phase HPLC purification:
   • Ultra-deep purification of API from residual synthesis isomers and impurities using C18 silica-gel columns, achieving greater than 99.5% chemical purity, the standard required for medical-grade psychoactive substances.

07Value chains and production pipelines

Industrial pipeline for GMP manufacture and intranasal-spray formulation of a peptidomimetic psychoplastogen

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. API biosynthesis or     │ ───> │ 2. Extraction & prep-HPLC  │
│    chemical synthesis (GMP)   │      │    purification                │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Sterile filtration      │ <─── │ 3. Formulation dissolution │
│    (0.22 μm)                    │      │    & buffering                 │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Aseptic fill into       │ ───> │ 6. Spray-dispenser          │
│    vials                        │      │    integration & packaging     │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: API biosynthesis or chemical synthesis (GMP)

A specialized GMP chemical reactor carries out multi-step fine organic synthesis of a non-hallucinogenic psychoplastogen candidate, or alternatively a genetically engineered yeast strain is fermented in a GMP bioreactor to biosynthesize native psilocybin, with cells lysed after several days of aerobic culture to release the product.

Stage 2: Extraction and preparative HPLC purification

The dried lysate or reaction mixture is dissolved and filtered to remove solids, then loaded onto a preparative HPLC system using C18 columns and a water-alcohol gradient; target-compound fractions are collected based on UV spectroscopy and freeze-dried into a crystalline API powder of high chemical purity.

Stage 3: Formulation dissolution and buffering

The purified API is dissolved in an aqueous buffer system formulated for nasal-mucosa compatibility and stability, with pH and osmolarity adjusted to match physiological tolerance.

Stage 4: Sterile filtration (0.22 μm)

The formulated solution passes through a 0.22 μm sterilizing-grade filter to remove any microbial contamination before fill-finish operations.

Stage 5: Aseptic fill into vials

The sterile-filtered solution is aseptically filled into single-dose vials under a GMP cleanroom environment, with in-process controls verifying fill volume and sterility.

Stage 6: Spray-dispenser integration and packaging

Filled vials are integrated with precision intranasal spray-dispenser mechanisms, then packaged and labeled for distribution to clinical trial sites or, pending approval, commercial pharmacy channels.